Cytrellis Biosystems Expands Global Presence with Regulatory Approvals for ellacor®
WOBURN, Mass., March 18, 2025 – Cytrellis Biosystems, a medical technology company focused on innovative aesthetic solutions, announced today that it has secured regulatory approvals from Health Canada and the Saudi Food and Drug Authority (SFDA). These authorizations pave the way for the commercialization of its groundbreaking ellacor® with Micro-Coring® technology in Canada and Saudi Arabia.
This expansion marks a crucial step in Cytrellis’s growth strategy, introducing cutting-edge aesthetic solutions to these key international markets. Both Canada and Saudi Arabia boast thriving and expanding aesthetic procedure markets. The Canadian market is projected to reach $7.2 billion by 2030, while the Saudi market is expected to reach $1.8 billion within the same timeframe.
“These approvals are a testament to our commitment to bringing innovative aesthetic solutions to a global audience,” stated Denise Dajles, President and CEO of Cytrellis Biosystems. “The market is experiencing rapid evolution. ellacor® offers a non-surgical alternative for individuals who are unsatisfied with the results of laser treatments and other energy-based devices, and who would prefer to avoid the invasiveness of surgery. With over 10,000 procedures successfully performed in the U.S., we are excited to make ellacor® available in these new markets.”
Cytrellis is launching immediately in Canada, and is working with a leading local distributor to ensure ellacor® is available in Saudi Arabia. These two markets join the company’s existing international presence in the United Arab Emirates. Health Canada and the SFDA are the respective governmental bodies responsible for the registration and oversight of medical devices, including aesthetic products, within their jurisdictions.
About ellacor® with Micro-Coring® Technology
The ellacor® system with Micro-Coring® technology represents a pioneering, minimally invasive in-office procedure. It is designed to remove sagging skin, effectively treat wrinkles, and rejuvenate the skin. The system received clearance from the U.S. Food and Drug Administration (FDA) in 2021. This innovative technology works at a micro-scale to target moderate to severe wrinkles in the mid and lower face.
Developed by Dr. William Austen, Jr., Chief of Plastic and Reconstructive Surgery and Chief of Burn Surgery at Massachusetts General Hospital (MGH), and Dr. Rox Anderson, the Lancer Endowed Chair in Dermatology and Director of the Wellman Center for Photomedicine at MGH, Micro-Coring is a proprietary technology that removes a small amount of skin surface area to stimulate the body’s natural healing response. It utilizes hollow needles to precisely remove micro-cores of both dermal and epidermal tissue. Importantly, this procedure does not involve surgery, thermal energy, or create visible scarring.
Indicated for use by qualified medical professionals, ellacor® with Micro-Coring® technology is authorized for adults aged 22 years or older, encompassing Fitzpatrick skin types I-IV. For more detailed information, visit www.ellacor.com.
